Macrophage Activation Syndrome
14
1
4
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.1%
1 terminated out of 14 trials
85.7%
-0.8% vs benchmark
14%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis
Anakinra in Dengue With Hyperinflammation ( AnaDen )
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
Assessment of Macrophage Activation syndromE in STill's Disease
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome